BAOTOU DONGBAO BIO-TECH CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.24 CNY | +3.15% |
|
+10.32% | -15.89% |
| Apr. 24 | Baotou Dongbao Bio-Tech Co.,Ltd Proposes Final Cash for the Year 2023 | CI |
| Apr. 23 | Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,717 | 2,635 | 3,110 | 4,185 | 4,452 | 3,698 |
| Enterprise Value (EV) 1 | 1,703 | 2,637 | 3,238 | 4,010 | 4,291 | 3,419 |
| P/E ratio | 50.2 x | 71.6 x | 169 x | 109 x | 40.7 x | 31.8 x |
| Yield | 0.81% | 0.6% | - | 0.09% | 0.35% | - |
| Capitalization / Revenue | 3.79 x | 5.36 x | 6.93 x | 6.84 x | 4.72 x | 3.79 x |
| EV / Revenue | 3.76 x | 5.36 x | 7.21 x | 6.55 x | 4.55 x | 3.51 x |
| EV / EBITDA | 23.2 x | 40.3 x | 47.7 x | 45 x | 20.4 x | 14.7 x |
| EV / FCF | 113 x | -12.3 x | -22.4 x | -192 x | -88.9 x | 25.9 x |
| FCF Yield | 0.88% | -8.11% | -4.46% | -0.52% | -1.12% | 3.87% |
| Price to Book | 2.29 x | 2.66 x | 3.14 x | 2.94 x | 2.91 x | 2.23 x |
| Nbr of stocks (in thousands) | 463,994 | 522,746 | 521,810 | 593,603 | 593,603 | 593,603 |
| Reference price 2 | 3.700 | 5.040 | 5.960 | 7.050 | 7.500 | 6.230 |
| Announcement Date | 4/18/19 | 4/21/20 | 4/14/21 | 4/25/22 | 3/21/23 | 4/23/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 452.7 | 491.8 | 448.8 | 612.2 | 943.4 | 974.5 |
| EBITDA 1 | 73.5 | 65.51 | 67.94 | 89.04 | 209.9 | 231.8 |
| EBIT 1 | 37.58 | 30.24 | 19.38 | 33.85 | 124.6 | 149.9 |
| Operating Margin | 8.3% | 6.15% | 4.32% | 5.53% | 13.21% | 15.38% |
| Earnings before Tax (EBT) 1 | 39.17 | 40.15 | 19.66 | 41.54 | 131.6 | 144.5 |
| Net income 1 | 33.98 | 35.61 | 18.45 | 36.48 | 109.4 | 119.9 |
| Net margin | 7.5% | 7.24% | 4.11% | 5.96% | 11.6% | 12.3% |
| EPS 2 | 0.0737 | 0.0704 | 0.0353 | 0.0647 | 0.1844 | 0.1959 |
| Free Cash Flow 1 | 15.03 | -213.7 | -144.3 | -20.87 | -48.26 | 132.1 |
| FCF margin | 3.32% | -43.46% | -32.16% | -3.41% | -5.12% | 13.56% |
| FCF Conversion (EBITDA) | 20.45% | - | - | - | - | 57% |
| FCF Conversion (Net income) | 44.23% | - | - | - | - | 110.23% |
| Dividend per Share 2 | 0.0300 | 0.0300 | - | 0.006000 | 0.0260 | - |
| Announcement Date | 4/18/19 | 4/21/20 | 4/14/21 | 4/25/22 | 3/21/23 | 4/23/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 2.37 | 128 | - | - | - |
| Net Cash position 1 | 13.6 | - | - | 175 | 161 | 279 |
| Leverage (Debt/EBITDA) | - | 0.0361 x | 1.881 x | - | - | - |
| Free Cash Flow 1 | 15 | -214 | -144 | -20.9 | -48.3 | 132 |
| ROE (net income / shareholders' equity) | 4.59% | 4.09% | 1.83% | 2.75% | 6.87% | 6.98% |
| ROA (Net income/ Total Assets) | 2.16% | 1.5% | 0.89% | 1.2% | 3.52% | 3.71% |
| Assets 1 | 1,570 | 2,368 | 2,082 | 3,044 | 3,105 | 3,231 |
| Book Value Per Share 2 | 1.620 | 1.900 | 1.900 | 2.400 | 2.570 | 2.790 |
| Cash Flow per Share 2 | 0.2100 | 0.1300 | 0.0900 | 0.3800 | 0.6000 | 1.260 |
| Capex 1 | 55.2 | 129 | 152 | 51.4 | 109 | 132 |
| Capex / Sales | 12.2% | 26.3% | 33.85% | 8.39% | 11.51% | 13.57% |
| Announcement Date | 4/18/19 | 4/21/20 | 4/14/21 | 4/25/22 | 3/21/23 | 4/23/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.89% | 430M | |
| +19.98% | 43.67B | |
| +20.67% | 22.51B | |
| +13.41% | 14.6B | |
| +14.32% | 13.74B | |
| +44.72% | 11.91B | |
| -8.37% | 7.04B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.42B |
- Stock Market
- Equities
- 300239 Stock
- Financials Baotou Dongbao Bio-Tech Co.,Ltd
